Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 11, 2019

Rafael starts trial of CPI-613 and mFFX for pancreatic cancer

Rafael Pharmaceuticals has commenced a Phase II trial to investigate the efficacy and safety of CPI-613 in combination with modified folfirinox (mFFX) for the treatment of patients with localised borderline and unresectable pancreatic cancer.

Rafael Pharmaceuticals has commenced a Phase II trial to investigate the efficacy and safety of CPI-613 in combination with modified folfirinox (mFFX) for the treatment of patients with localised borderline and unresectable pancreatic cancer.

CPI-613 is a drug developed by Rafael to target the altered regulation of metabolic processes of cancer cells, while mFFX is a standard combination of drugs.

Rafael plans to enrol 33 subjects with Eastern Cooperative Oncology Group (ECOG) performance status 0-1 as part of the open-label, single-armed trial.

Patients will receive the study drug combination over a period of six months and will be followed until death or three years from the date of completion of the trial.

“We hope to identify a strategy to extend the lives of patients with pancreatic cancer, and increase the patient eligibility for surgery.”

The trial’s primary endpoint is to identify the potential increase in overall survival (OS) and to further evaluate the safety of the CPI-613+ mFFX combination.

Its secondary endpoints comprise progression-free survival (PFS), time to progression (TTP), resection margins and others.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The Phase II trial will be conducted in collaboration with University Hospitals Cleveland Medical Center in the US.

The trial’s lead investigator Jeffery Hardacre said: “Through this trial, we hope to identify a strategy to extend the lives of patients with pancreatic cancer, and increase the patient eligibility for surgery for those with locally advanced disease.”

Rafael previously assessed the safety, tolerability, and efficacy of the CPI-613 and mFFX combination in patients with first-line metastatic pancreatic cancer.

The study included a single-centre, open-label, dose-escalation design and included 20 patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU